Pharmaceuticals company Zydus Lifesciences announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from operations at Rs 52,370 million, up 20% over Q2FY24. Research & Development (R&D;) investments for the Q2FY25 stood at Rs 4,800 million (9.2% of revenues). EBITDA for the quarter was Rs 14,614 million, up 28% YoY. EBITDA margin for the quarter stood at 27.9% which is an improvement of 170 bps on a YoY basis. Net Profit for the Q2FY25 was Rs 9,112 million, up 14% YoY. Capex (organic) for the quarter was Rs 3,017 million. H1FY25 Financial Highlights: Revenue from operations at Rs 114,445 million, up 20% over H1FY24. Research & Development (R&D;) investments stood at Rs 8,725 million (7.6% of revenues). EBITDA was Rs 35,454 million, up 34% YoY. EBITDA margin stood at 31%, which is an improvement of 310 bps over H1FY24. Net Profit was Rs 23,311 million, up 24% YoY. Capex (organic) for the half year was Rs 6,031 million. Net Debt to Equity ratio as on 30th September, 2024 was -0.12x while Net Debt to EBITDA stood at -0.41x at the end of H1FY25. Net Cash (negative Net Debt) as on H1FY25 was Rs 25,906 million. Sharvil Patel, Managing Director - Zydus Lifesciences, said: Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India Geography business were particularly noteworthy. With a focus on quality excellence, we will continue to align our processes and strengthen compliance. We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions, keeping patient centricity at the core. Result PDF